Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

Trial marks second study for volanesorsen in a rare, genetic lipid disorder CARLSBAD, Calif., and CAMBRIDGE, Mass., Nov. 5, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and its wholly owned subsidiary, Akcea Therapeutics, today announced the start of a Phase 3 study to evaluate the efficacy and safety of volanesorsen in patients with familial partial lipodystrophy (FPL). Akcea is currently conducting an international, multi-center Phase 3 study of volanesorsen in patients with Familial Chylomicronemia Syndrome (FCS). Akcea is developing and plans to commercialize volanesorsen for two ultra-rare diseases, FCS and FPL.

The release as fetched from its publisher. ionis.com ↗